Elicio Therapeutics (ELTX) Other Non-Current Assets (2021 - 2026)

Elicio Therapeutics has reported Other Non-Current Assets for 6 years, with the latest figure at $706000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 1.15% year-over-year to $706000.0; the trailing twelve-month figure through Mar 2026 stood at $706000.0 (up 1.15% YoY), and the FY2025 full-year result was $770000.0, up 28.33% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $706000.0, down from $770000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.8 million in Q4 2022, with the low at $75000.0 in Q3 2022.
• Historically, Other Non-Current Assets has averaged $1.2 million across 5 years, with a median of $706000.0 in 2026.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 3633.33% — and 2024, when it tumbled 78.57%.
• Elicio Therapeutics' Other Non-Current Assets stood at $2.8 million in 2022, then slipped by 1.16% to $2.8 million in 2023, then plunged by 78.57% to $600000.0 in 2024, then advanced by 28.33% to $770000.0 in 2025, then slipped by 8.31% to $706000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $706000.0 (Q1 2026), $770000.0 (Q4 2025), and $770000.0 (Q3 2025), per Business Quant data.